Physician profile
Dhananjay Kumar
NPI 1669461075
$1,291.07
in general payments reported to CMS, 2019-2025
21 companies · $419 in 2025
The $419 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15.80 · 2020: $15.90 · 2022: $139 · 2023: $204 · 2024: $498 · 2025: $419.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,121.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,120.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $321.57 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $169.98 | 2022-2025 | |
| Abbott Laboratories | $110.44 | 2022-2025 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $104.32 | 2022-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $104.30 | 2024-2025 | Farxiga, Airsupra |
| Amgen INC. | $62.12 | 2022-2025 | Repatha, Evenity, Otezla |
| Lilly USA, LLC | $56.39 | 2025 | Jardiance, Zepbound, Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.92 | 2024-2025 | Jardiance |
| Cranial Technologies, INC | $48.03 | 2019-2025 | Doc Band |
| Ultragenyx Pharmaceutical INC. | $36.47 | 2024 | Crysvita |
| Abbvie INC. | $31.78 | 2024 | |
| Exact Sciences Corporation | $29.52 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Hologic Sales and Service, LLC | $24.62 | 2025 | Aptima, Thinprep 2000 Processor |
| Olympus America INC. | $23.74 | 2025 | Itind System |
| Astellas Pharma US INC | $22.36 | 2023 | Veozah |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $21.38 | 2025 | Rexulti |
| Sanofi-Aventis U.S. LLC | $17.03 | 2025 | |
| Janssen Pharmaceuticals, INC | $16.65 | 2022 | |
| Inari Medical, INC. | $16.02 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Rgh Enterprises LLC | $13.71 | 2025 | |
| Dynavax Technologies Corporation | $10.72 | 2024 | Heplisav-B |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dhananjay Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.